Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989431 | 0.85 | HCRTR2 (0.44) | GRM5GRM1HCRTR2HCRTR1DPP4 | |
| SCHEMBL6985742 | 0.85 | FABP4 (0.44) | FABP4HCRTR2HCRTR1SCD5 | |
| SCHEMBL6989539 | 0.84 | SCD5 (0.55) | FABP4HCRTR2HCRTR1SCD5CYP3A4 | |
| SCHEMBL21078209 | 0.81 | KDM4E (0.47) | HCRTR2HCRTR1DPP4JAK1KDM4E | |
| SCHEMBL6989978 | 0.81 | SCD5 (0.51) | FABP4HCRTR2HCRTR1DPP4SCD5 | |
| SCHEMBL6988342 | 0.81 | NAMPT (0.58) | FABP4HCRTR2HCRTR1KDM4ESCD5 | |
| SCHEMBL6989618 | 0.80 | FABP4 (0.52) | FABP4HCRTR2HCRTR1SCD5CYP3A4 | |
| SCHEMBL6989529 | 0.80 | NAMPT (0.50) | FABP4HCRTR2HCRTR1SCD5 | |
| SCHEMBL6989556 | 0.80 | HCRTR1 (0.48) | FABP4HCRTR2HCRTR1SCD5CYP3A4 | |
| SCHEMBL6987416 | 0.80 | FABP4 (0.43) | FABP4HCRTR2HCRTR1DPP4SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | FABP4 1/4885GRM5 1614/4885GRM1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.